Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

AI partners Microsoft and OpenAI’s cooling relationship cools further with Amgen’s switch from Copilot to ChatGPT.

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, prevalent gastrointestinal side effects are leading the company to use a slow | ...